On August 30 2022, Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, announced details of its strategic expansion plan following its $100 million Series B funding round in January 2022. Ori has augmented key expertize, personnel and facilities globally in order to rapidly transition into the launch of its innovative cell and gene therapy (CGT) manufacturing platform.
This news has been reported by key publications. Here is a list of where you can find out more:
Ori in the news
Biospace
BioSpace.com is the most comprehensive Life Science industry news and information source. We cover news across the biotech, pharmaceutical and medical device industries. We also provide industry-specific career news, advice and resources to support and inspire ongoing professional development.
Article: Movers & Shakers: Galera, Verily, Avid and More Tap New Execs
Endpoints News
Helps drug development executives stay informed with biopharma news. Reported by a global team of journalists — led by founder John Carroll — Endpoints covers news as it happens and delivers twice-daily email reports in the business of discovering, funded by subscribers and clients.
Article: Jay Bradner’s NIBR exit sets off a succession plan at Merck; Dyne and MorphoSys fill major R&D roles
The Pharma Letter
The Pharma Letter is a pharmaceutical, generics and biotechnology news and analysis service.
Article: Ori Biotech follows up financing with appointments and new facility
Contract Pharma
Contract Pharma is the multi media information outlet dedicated to bio/pharma outsourcing. From drug development to manufacturing, we cover the latest developments, views and opinions from industry leaders in print and online.
Article: Ori Biotech Expands Expertise and Personnel, Adds New Facilities
